Peritonitis (Gastrointestinal) - Drugs in Development, 2021

September 2021 | 53 pages | ID: P57D4D2B98D6EN
Global Markets Direct

Abstracts

Peritonitis (Gastrointestinal) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Drugs In Development, 2021, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritonitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Peritonitis - Overview
Peritonitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peritonitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peritonitis - Companies Involved in Therapeutics Development
Arrevus Inc
AstraZeneca Plc
Ayuvis Research Inc
Cantargia AB
Hunan Sanqing Pharmaceutical Co Ltd
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Nosopharm SAS
Oncodesign SA
Reponex Pharmaceuticals AS
SynAct Pharma AB
Peritonitis - Drug Profiles
(avibactam + aztreonam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARV-1502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVR-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAN-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceforanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOSO-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ODS-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NLRP3 for Inflammatory Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peritonitis - Dormant Projects
Peritonitis - Product Development Milestones
Featured News & Press Releases
Apr 26, 2021: Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Peritonitis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Peritonitis - Pipeline by Arrevus Inc, 2021
Peritonitis - Pipeline by AstraZeneca Plc, 2021
Peritonitis - Pipeline by Ayuvis Research Inc, 2021
Peritonitis - Pipeline by Cantargia AB, 2021
Peritonitis - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2021
Peritonitis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2021
Peritonitis - Pipeline by Nosopharm SAS, 2021
Peritonitis - Pipeline by Oncodesign SA, 2021
Peritonitis - Pipeline by Reponex Pharmaceuticals AS, 2021
Peritonitis - Pipeline by SynAct Pharma AB, 2021
Peritonitis - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peritonitis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021